New inhibitors of tubulin polymerisation

Bibliography

• PANDA D, JORDAN MA, CHU KC, WILSON L: Differentialeffects of vinblastine on polymerization and dynamics at opposite microtubule ends. J. Biol. Chem. (1996) 271:29807–29812.
   PubMedGoogle Scholar
• DHAMODHARAN R, JORDAN MA, THROWER D, WILSON L, WADSWORTH P: Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol Biol. Cell (1995) 6:1215–1229.
   PubMed Web of Science ®Google Scholar
• TER HAAR E: Taxanes and other microtubulestabilising agents. Exp. Opin. Ther. Patents (1998) 8(5):571–586.
   Google Scholar
• •A very good overview of new taxane derivatives.
   Google Scholar
• JORDAN A, HADFIELD JA, LAWRENCE NJ, MCGOWN AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. (1998) 18:259–296.
   PubMed Web of Science ®Google Scholar
• GOKBUGET N, HOELZER D: Vindesine in the treatment of leukaemia. Leuk. Lymphoma (1997) 26:497–506.
   PubMed Web of Science ®Google Scholar
• BUDMAN DR: Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest. (1997) 15:475–490.
   PubMedGoogle Scholar
• KRUCZYNSKI A, COLPAERT F, TARAYRE JP et al.:Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother. Pharmacol. (1998) 41:437–447.
   PubMed Web of Science ®Google Scholar
• KRUCZYNSKI A, BARRET JM, ETIEVANT C et al: Antimi-totic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol. (1998) 55:635–648.
   PubMed Web of Science ®Google Scholar
• •Comprehensive biochemical characterisation of the new drug vinflunine.
   Google Scholar
• OROSZ F, KOVACS J, LOW P et al.: Interaction of a new bis-indol derivative, KAR-2 with tubulin and its antimi-totic activity. Br. J. Pharmacol. (1997) 121:947–954.
   PubMedGoogle Scholar
• SHI Q, VERDIER PINARD P, BROSSI A et al.: Antitumor agents. 172. Synthesis and biological evaluation of novel deacetamidothiocolchicin-7-ols and ester analogs as antitubulin agents. J. Med. Chem. (1997) 40:961–966.
   Google Scholar
• SHI Q, CHE K, CHEN X et al: Antitumor agents. 183.Syntheses, conformational analyses, and antitubulin activity of allothiocolchicinoids. J. Org. Chem. (1998) 63:4018–4025.
   Google Scholar
• SHI Q, CHEN K, BROSSI A et al.: Antitumor agents.184.Syntheses and antitubulin activity of compounds derived from reaction of thiocolchicone with amines: Lactams, alcohols, and ester analogs of allocolchici-noids. Helv. Chim. Acta (1998) 81:1023–1037.
   Google Scholar
• MILLER TA, VACHASPATI PR, LABROLI MA et al.: Thesynthesis and evaluation of benzannelated-azatoxins: the benzazatoxins. Bioorg. Merl. Chem. Lett. (1998) 8:1065–1070.
   PubMedGoogle Scholar
• PETTIT GR, SINGH SB, HAMEL E et al.: Isolation andstructure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia (1989) 45:209–211.
   PubMedGoogle Scholar
• EL ZA, DEGEN D, DRABEK S et al.: In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs (1993) 4:19–25.
   PubMedGoogle Scholar
• MCGOWN AT, FOX BW: Differential cytotoxicity of combretastatins Al and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chem other. Pharmacol (1990) 26:79–81.
   PubMedGoogle Scholar
• DARK GG, HILL SA, PRISE VE et al.: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. (1997) 57:1829–1834.
   PubMed Web of Science ®Google Scholar
• IYER S, CHAPLIN DJ, ROSENTHAL DS et al.: Induction ofapoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combreta-statin A-4. Cancer Res. (1998) 58:4510–4514.
   PubMed Web of Science ®Google Scholar
• DORR RT, DVORAKOVA K, SNEAD K et al.: Antitumoractivity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest. New Drugs (1996) 14:131–137.
   PubMedGoogle Scholar
• OHSUMI K, NAKAGAWA R, FUKUDA Y et al.: Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relation-ships. J. Merl. Chem. (1998) 41:3022–3032.
   PubMed Web of Science ®Google Scholar
• OHSUMI K, HATANAKA T, FUJITA K eta].: Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg. Merl. Chem. Lett. (1998) 8:3153–3158.
   Google Scholar
• HATANAKA T, FUJITA K, OHSUMI K et al: Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg. Merl. Chem. Lett. (1998) 8:3371–3374.
   PubMedGoogle Scholar
• SHIRAI R, TAKAYAMA H, NISHIKAWA A, KOISO Y, HASHIMOTO Y: Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg. Med. Chem. Lett. (1998) 8:1997–2000.
   PubMedGoogle Scholar
• PINNEY KG, BOUNDS AD, DINGEMAN KM et al.: A new anti-tubulin agent containing the benzo[b]thiophene ring system. Bioorg. Med. Chem. Lett. (1999) 9:1081–1086.
   PubMedGoogle Scholar
• GASTPAR R: Immunchemische Protein-Tyrosin-Kinase-Assays fiir die wirkmechanistischen Untersuchungen neuer 2-Phenylindol- und 2-Phenylbenzo[b]thiophenderivate. Doctoral Theses, Univ. Regensburg, Germany (1997).
   Google Scholar
• GASTPAR R, GOLDBRUNNER M, MARKO D, VON ANGERER E: Methoxy-substituted 3-formy1-2-phenylindoles inhibit tubulin polymerization. J. Med. Chem. (1998) 41:4965–4972.
   PubMed Web of Science ®Google Scholar
• GOLDBRUNNER M, LOIDL G, POLOSSEK T, MANNSCHRECK A, VON ANGERER E: Inhibition of tubulin polymerization by 5,6-dihydro-indolo[2,1-a]isoquinoline derivatives. J. Med. Chem. (1997) 40:3524–3533.
   PubMed Web of Science ®Google Scholar
• BEUTLER JA, HAMEL E, VLIETINCK AJ et al: Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J. Med. Chem. (1998) 41:2333–2338.
   PubMed Web of Science ®Google Scholar
• XIA Y, YANG ZY, XIA P et al: Antitumor agents. 181. Synthesis and biological evaluation of 6, 7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-pheny1-4-quinolones as a new class of antimitotic antitumor agents. J. Med. Chem. (1998) 41:1155–1162.
   Google Scholar
• CHEN K, KUO SC, HSIEH MC et al: Antitumor agents. 174. 2',3',4',5,6,7-Substituted 2-pheny1-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. (1997) 40:2266–2275.
   Google Scholar
• YOSHIMATSU K, YAMAGUCHI A, YOSHINO H, KOYANAGI N, KITOH K: Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibi-tion of mitosis by binding to the colchicine site of tubulin. Cancer Res. (1997) 57:3208–3213.
   PubMed Web of Science ®Google Scholar
• •This preclinical study elaborates the advantages of E7010 over other drugs in the treatment of resistant tumours.
   Google Scholar
• YAMAMOTO K, NODA K, YOSHIMURA A et al: Phase I study of E7010. Cancer Chemother. Pharmacol. (1998) 42:127–134.
   PubMed Web of Science ®Google Scholar
• CHEN X, PINE P, KNAPP AM, TUSE D, LADEROUTE KR: Oncocidin Al: a novel tubulin-binding drug with antitumor activity against human breast and ovarian carcinoma xenografts in nude mice. Biochem. Pharmacol. (1998) 56:623–633.
   PubMedGoogle Scholar
• FOTSIS T, ZHANG Y, PEPPER MS et al.: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature (1994) 368:237–239.
   PubMed Web of Science ®Google Scholar
• ••The first report on the inhibition of tubulin polymerisationby oestrogens.
   Google Scholar
• CUSHMAN M, HE HM, KATZENELLENBOGEN JA, LIN CM, HAMEL E: Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymeri-zation by binding to the colchicine binding site. J. Med. Chem. (1995) 38:2041–2049.
   PubMed Web of Science ®Google Scholar
• MILLER TA, BULMAN AL, THOMPSON CD, GARST ME, MACDONALD TL: Synthesis and structure-activity profiles of A-homoestranes, the estratropones. J. Med. Chem. (1997) 40:3836–3841.
   PubMedGoogle Scholar
• PONCET J: The dolastatins, a family of promisingantineoplastic agents. Curr. Pharm. Des. (1999) 5:139–162.
   PubMed Web of Science ®Google Scholar
• BAI R, TAYLOR GF, SCHMIDT JM et al.: Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. Mol. Pharmacol. (1995) 47:965–976.
   PubMed Web of Science ®Google Scholar
• KALEMKERIAN GP, OU X, ADIL MR et al.: Activity of dolastatin 10 against small-cell lung cancer in vitro and in viva induction of apoptosis and bc1-2 modifica-tion. Cancer Chemother. Pharmacol. (1999) 43:507–515.
   PubMed Web of Science ®Google Scholar
• •An interesting report on preclinical data of dolastatin 10 and their relevance for clinical studies.
   Google Scholar
• HARRIGAN GG, LUESCH H, YOSHIDA WY et al.: Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J. Natl. Prod. (1998) 61:1075–1077.
   PubMed Web of Science ®Google Scholar
• JORDAN MA, WALKER D, DE AM, BARLOZZARI T, PANDA D: Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry (1998) 37:17571–17578.
   PubMedGoogle Scholar
• WAGNER MM, PAUL DC, SHIH C et al.: In vitro pharma-cology of cryptophycin 52 (LY 355703) in human tumor cell lines. Cancer Chemother. Pharmacol. (1999) 43:115–125.
   PubMed Web of Science ®Google Scholar
• ••A thorough study on the effect of cryptophycin 52 on theproliferation of tumour cells including various drug-resistant lines.
   Google Scholar
• PANDA D, HIMES RH, MOORE RE, WILSON L, JORDAN MA: Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1. Biochemistry (1997) 36:12948–12953.
   PubMed Web of Science ®Google Scholar
• MOOBERRY SL, BUSQUETS L, TIEN G: Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. Int. J. Cancer (1997) 73:440–448.
   PubMed Web of Science ®Google Scholar
• PANDA D, DELUCA K, WILLIAMS D, JORDAN MA, WILSON L: Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc. Natl. Acad. Sci. USA (1998) 95:9313–9318.
   PubMed Web of Science ®Google Scholar
• GEORG GI, ALI SM, STELLA VJ, WAUGH WN, HIMES RH: Halohydrin analogues of cryptophycin 1: synthesis and biological activity. Bioorg. Med. Chem. Lett. (1998) 8:1959–1962.
   PubMedGoogle Scholar
• ANDERSON HJ, COLEMAN JE, ANDERSEN RJ, ROBERGE M:Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother. Pharmacol. (1997) 39:223–226.
   PubMed Web of Science ®Google Scholar